AZD3147

AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K[1].

Product Specifications

CAS Number

[1101810-02-9]

UNSPSC

12352005

Target

MTOR

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/azd3147.html

Purity

99.93

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1(C2=NC(C3=CC=C(C=C3)NC(NCCO)=S)=NC(N4[C@H](COCC4)C)=C2)CC1)(C5CC5)=O

Molecular Formula

C24H31N5O4S2

Molecular Weight

517.66

References & Citations

[1]Kurt G Pike, et al. Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2. J Med Chem. 2015 Mar 12;58 (5) :2326-49.|[2]Michaela Kunova Bosakova, et al. Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies. Hum Mol Genet. 2018 Mar 15;27 (6) :1093-1105.|[3]Rebecca Waetzig, et al. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells. Int J Med Sci. 2021 Jan 1;18 (1) :137-149.